Published in J Biol Chem on January 24, 2001
Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell (2006) 12.72
The hippo signaling pathway in development and cancer. Dev Cell (2010) 10.54
Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon. Proc Natl Acad Sci U S A (2006) 8.01
The Hippo-YAP pathway in organ size control and tumorigenesis: an updated version. Genes Dev (2010) 6.05
Hippo signaling: growth control and beyond. Development (2011) 5.25
The TEAD/TEF family of transcription factor Scalloped mediates Hippo signaling in organ size control. Dev Cell (2008) 4.90
The Hippo pathway in organ size control, tissue regeneration and stem cell self-renewal. Nat Cell Biol (2011) 4.63
The Hippo pathway: regulators and regulations. Genes Dev (2013) 4.55
Mutant p53: one name, many proteins. Genes Dev (2012) 4.33
The Hippo-YAP pathway: new connections between regulation of organ size and cancer. Curr Opin Cell Biol (2008) 3.63
RASSF1A elicits apoptosis through an MST2 pathway directing proapoptotic transcription by the p73 tumor suppressor protein. Mol Cell (2007) 3.47
YAP regulates neural progenitor cell number via the TEA domain transcription factor. Genes Dev (2008) 3.16
Defects in yolk sac vasculogenesis, chorioallantoic fusion, and embryonic axis elongation in mice with targeted disruption of Yap65. Mol Cell Biol (2006) 3.15
The two faces of Hippo: targeting the Hippo pathway for regenerative medicine and cancer treatment. Nat Rev Drug Discov (2013) 3.03
The ubiquitin-protein ligase Itch regulates p73 stability. EMBO J (2005) 2.38
The transcriptional co-activator TAZ interacts differentially with transcriptional enhancer factor-1 (TEF-1) family members. Biochem J (2005) 2.15
Tyrosine phosphorylation controls Runx2-mediated subnuclear targeting of YAP to repress transcription. EMBO J (2004) 2.12
Rescue of Hippo coactivator YAP1 triggers DNA damage-induced apoptosis in hematological cancers. Nat Med (2014) 2.03
Structural insights into the YAP and TEAD complex. Genes Dev (2010) 2.00
Functional association between Wwox tumor suppressor protein and p73, a p53 homolog. Proc Natl Acad Sci U S A (2004) 1.91
Complex transcriptional effects of p63 isoforms: identification of novel activation and repression domains. Mol Cell Biol (2002) 1.89
The p53 family and programmed cell death. Oncogene (2008) 1.81
Yorkie: the final destination of Hippo signaling. Trends Cell Biol (2010) 1.65
Splitting p63. Am J Hum Genet (2002) 1.62
The Lats2 tumor suppressor augments p53-mediated apoptosis by promoting the nuclear proapoptotic function of ASPP1. Genes Dev (2010) 1.50
Pax3 and hippo signaling coordinate melanocyte gene expression in neural crest. Cell Rep (2014) 1.46
Yap tunes airway epithelial size and architecture by regulating the identity, maintenance, and self-renewal of stem cells. Dev Cell (2014) 1.42
YAP modifies cancer cell sensitivity to EGFR and survivin inhibitors and is negatively regulated by the non-receptor type protein tyrosine phosphatase 14. Oncogene (2012) 1.36
Emerging roles of TEAD transcription factors and its coactivators in cancers. Cancer Biol Ther (2013) 1.34
Therapeutic prospects for p73 and p63: rising from the shadow of p53. Drug Resist Updat (2008) 1.32
The transcriptional repressor ZEB regulates p73 expression at the crossroad between proliferation and differentiation. Mol Cell Biol (2001) 1.29
Serum deprivation inhibits the transcriptional co-activator YAP and cell growth via phosphorylation of the 130-kDa isoform of Angiomotin by the LATS1/2 protein kinases. Proc Natl Acad Sci U S A (2013) 1.27
MDM2 is required for suppression of apoptosis by activated Akt1 in salivary acinar cells. Mol Cell Biol (2006) 1.23
PTPN14 interacts with and negatively regulates the oncogenic function of YAP. Oncogene (2012) 1.17
Yes-associated protein regulates the hepatic response after bile duct ligation. Hepatology (2012) 1.15
Hippo signaling at a glance. J Cell Sci (2010) 1.14
ATM regulates a RASSF1A-dependent DNA damage response. Curr Biol (2009) 1.14
Cooperation between dE2F1 and Yki/Sd defines a distinct transcriptional program necessary to bypass cell cycle exit. Genes Dev (2011) 1.13
JNK phosphorylates Yes-associated protein (YAP) to regulate apoptosis. Cell Death Dis (2010) 1.13
Regulation of p73 activity by post-translational modifications. Cell Death Dis (2012) 1.12
WW domain interactions regulate the Hippo tumor suppressor pathway. Cell Death Dis (2011) 1.09
The Angiomotins--from discovery to function. FEBS Lett (2014) 1.07
Yes-associated protein 65 (YAP) expands neural progenitors and regulates Pax3 expression in the neural plate border zone. PLoS One (2011) 1.05
The Hippo pathway kinase Lats2 prevents DNA damage-induced apoptosis through inhibition of the tyrosine kinase c-Abl. Cell Death Differ (2013) 1.04
YAP dysregulation by phosphorylation or ΔNp63-mediated gene repression promotes proliferation, survival and migration in head and neck cancer subsets. Oncogene (2010) 1.04
Tumor suppressor WWOX binds to ΔNp63α and sensitizes cancer cells to chemotherapy. Cell Death Dis (2013) 1.02
Amot130 adapts atrophin-1 interacting protein 4 to inhibit yes-associated protein signaling and cell growth. J Biol Chem (2013) 1.01
Loss of Yes-associated protein (YAP) expression is associated with estrogen and progesterone receptors negativity in invasive breast carcinomas. Breast Cancer Res Treat (2011) 1.00
The role of the Hippo pathway in human disease and tumorigenesis. Clin Transl Med (2014) 0.99
YAP activation protects urothelial cell carcinoma from treatment-induced DNA damage. Oncogene (2015) 0.96
Emerging evidence on the role of the Hippo/YAP pathway in liver physiology and cancer. J Hepatol (2015) 0.95
c-Abl antagonizes the YAP oncogenic function. Cell Death Differ (2014) 0.92
Interaction of the deubiquitinating enzyme Ubp2 and the e3 ligase Rsp5 is required for transporter/receptor sorting in the multivesicular body pathway. PLoS One (2009) 0.92
The hippo pathway in heart development, regeneration, and diseases. Circ Res (2015) 0.91
ATM kinase enables the functional axis of YAP, PML and p53 to ameliorate loss of Werner protein-mediated oncogenic senescence. Cell Death Differ (2013) 0.91
Stxbp4 regulates DeltaNp63 stability by suppression of RACK1-dependent degradation. Mol Cell Biol (2009) 0.90
Salvador protein is a tumor suppressor effector of RASSF1A with hippo pathway-independent functions. J Biol Chem (2011) 0.90
p73 as a pharmaceutical target for cancer therapy. Curr Pharm Des (2011) 0.90
What do mechanotransduction, Hippo, Wnt, and TGFβ have in common? YAP and TAZ as key orchestrating molecules in ocular health and disease. Exp Eye Res (2013) 0.90
c-Abl phosphorylation of ΔNp63α is critical for cell viability. Cell Death Dis (2010) 0.90
Regulation of p73 by Hck through kinase-dependent and independent mechanisms. BMC Mol Biol (2007) 0.89
YAP1 acts as oncogenic target of 11q22 amplification in multiple cancer subtypes. Oncotarget (2014) 0.89
Structural and functional insights into the TEAD-YAP complex in the Hippo signaling pathway. Protein Cell (2011) 0.89
YAP regulates the expression of Hoxa1 and Hoxc13 in mouse and human oral and skin epithelial tissues. Mol Cell Biol (2015) 0.87
Screening for E3-ubiquitin ligase inhibitors: challenges and opportunities. Oncotarget (2014) 0.86
Proline-rich Gla protein 2 is a cell-surface vitamin K-dependent protein that binds to the transcriptional coactivator Yes-associated protein. Proc Natl Acad Sci U S A (2007) 0.86
Hippo signaling is required for Notch-dependent smooth muscle differentiation of neural crest. Development (2015) 0.86
Cataloging and organizing p73 interactions in cell cycle arrest and apoptosis. Nucleic Acids Res (2008) 0.86
Daxx mediates activation-induced cell death in microglia by triggering MST1 signalling. EMBO J (2011) 0.85
Loss of RASSF1A synergizes with deregulated RUNX2 signaling in tumorigenesis. Cancer Res (2012) 0.84
Decreased expression of Yes-associated protein is associated with outcome in the luminal A breast cancer subgroup and with an impaired tamoxifen response. BMC Cancer (2014) 0.84
α-TEA cooperates with chemotherapeutic agents to induce apoptosis of p53 mutant, triple-negative human breast cancer cells via activating p73. Breast Cancer Res (2011) 0.84
AMPK couples p73 with p53 in cell fate decision. Cell Death Differ (2014) 0.83
Hippo and rassf1a Pathways: A Growing Affair. Mol Biol Int (2012) 0.83
gga-miR-375 plays a key role in tumorigenesis post subgroup J avian leukosis virus infection. PLoS One (2014) 0.82
A functional variant rs1820453 in YAP1 and breast cancer risk in Chinese population. PLoS One (2013) 0.82
Protein kinase C-dependent phosphorylation regulates the cell cycle-inhibitory function of the p73 carboxy terminus transactivation domain. Mol Cell Biol (2009) 0.82
JNK Signaling: Regulation and Functions Based on Complex Protein-Protein Partnerships. Microbiol Mol Biol Rev (2016) 0.81
High-throughput methods for identification of protein-protein interactions involving short linear motifs. Cell Commun Signal (2015) 0.81
Polyomavirus small T antigen interacts with yes-associated protein to regulate cell survival and differentiation. J Virol (2014) 0.81
YAP enhances the pro-proliferative transcriptional activity of mutant p53 proteins. EMBO Rep (2015) 0.81
Alteration of TEAD1 expression levels confers apoptotic resistance through the transcriptional up-regulation of Livin. PLoS One (2012) 0.81
Two-signal requirement for growth-promoting function of Yap in hepatocytes. Elife (2015) 0.81
Tyrosine phosphorylation of WW proteins. Exp Biol Med (Maywood) (2015) 0.80
PML Surfs into HIPPO Tumor Suppressor Pathway. Front Oncol (2013) 0.80
Depletion of CABYR-a/b sensitizes lung cancer cells to TRAIL-induced apoptosis through YAP/p73-mediated DR5 upregulation. Oncotarget (2016) 0.79
Prenatal exposure to dietary fat induces changes in the transcriptional factors, TEF and YAP, which may stimulate differentiation of peptide neurons in rat hypothalamus. PLoS One (2013) 0.78
Hippo signaling: to die or not to die. Cell Death Differ (2013) 0.78
Alcohol interacts with genetic alteration of the Hippo tumor suppressor pathway to modulate tissue growth in Drosophila. PLoS One (2013) 0.78
p73-Binding Partners and Their Functional Significance. Int J Proteomics (2011) 0.78
Allergic Rhinitis in Preschool Children and the Clinical Utility of FeNO. Allergy Asthma Immunol Res (2017) 0.77
The hippo signaling pathway: implications for heart regeneration and disease. Clin Transl Med (2014) 0.76
Overexpression of YAP1 induces immortalization of normal human keratinocytes by blocking clonal evolution. Histochem Cell Biol (2010) 0.75
Neomorphic mutations create therapeutic challenges in cancer. Oncogene (2016) 0.75
Impaired liver regeneration in aged mice can be rescued by silencing Hippo core kinases MST1 and MST2. EMBO Mol Med (2016) 0.75
Targeting the Hippo Signaling Pathway for Tissue Regeneration and Cancer Therapy. Genes (Basel) (2016) 0.75
A growing role for the Hippo signaling pathway in the heart. J Mol Med (Berl) (2017) 0.75
Yap/Taz transcriptional activity is essential for vascular regression via Ctgf expression and actin polymerization. PLoS One (2017) 0.75
Splice variant insertions in the C-terminus impairs YAP's transactivation domain. Biochem Biophys Rep (2016) 0.75
Investigation of the Possible Role of the Hippo/YAP1 Pathway in Asthma and Allergy. Allergy Asthma Immunol Res (2017) 0.75
Mdm2 promotes the rapid degradation of p53. Nature (1997) 21.26
pEMBL: a new family of single stranded plasmids. Nucleic Acids Res (1983) 19.19
Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature (1991) 9.21
Novel bacteriophage lambda cloning vector. Proc Natl Acad Sci U S A (1980) 8.97
mdm2 expression is induced by wild type p53 activity. EMBO J (1993) 8.01
Participation of p53 cellular tumour antigen in transformation of normal embryonic cells. Nature (1985) 6.86
Signal transducing molecules and glycosyl-phosphatidylinositol-linked proteins form a caveolin-rich insoluble complex in MDCK cells. J Cell Biol (1993) 6.62
Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol Cell Biol (1988) 6.44
Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53. Cell (1990) 6.37
The importance of being proline: the interaction of proline-rich motifs in signaling proteins with their cognate domains. FASEB J (2000) 6.26
Plasmids pEMBLY: new single-stranded shuttle vectors for the recovery and analysis of yeast DNA sequences. Gene (1985) 5.73
Wild-type p53 can inhibit oncogene-mediated focus formation. Proc Natl Acad Sci U S A (1989) 5.40
The WW domain of Yes-associated protein binds a proline-rich ligand that differs from the consensus established for Src homology 3-binding modules. Proc Natl Acad Sci U S A (1995) 4.52
A general method to select for M13 clones carrying base pair substitution mutants constructed in vitro. Nucleic Acids Res (1983) 4.14
ATM-dependent phosphorylation of Mdm2 on serine 395: role in p53 activation by DNA damage. Genes Dev (2001) 4.06
A human hepatitis B viral enhancer element. EMBO J (1985) 3.94
A proline-rich motif within the matrix protein of vesicular stomatitis virus and rabies virus interacts with WW domains of cellular proteins: implications for viral budding. J Virol (1999) 3.92
Generation of oscillations by the p53-Mdm2 feedback loop: a theoretical and experimental study. Proc Natl Acad Sci U S A (2000) 3.74
The yeast homologue of U3 snRNA. EMBO J (1987) 3.74
Interaction of c-Abl and p73alpha and their collaboration to induce apoptosis. Nature (1999) 3.50
Wild-type p53 can down-modulate the activity of various promoters. Proc Natl Acad Sci U S A (1991) 3.45
Guidelines for the use and interpretation of assays for monitoring cell death in higher eukaryotes. Cell Death Differ (2009) 3.44
Induction of apoptosis in HeLa cells by trans-activation-deficient p53. Genes Dev (1995) 3.40
Two distinct mechanisms regulate the levels of a cellular tumor antigen, p53. Mol Cell Biol (1983) 3.39
Identification of a minimal transforming domain of p53: negative dominance through abrogation of sequence-specific DNA binding. Mol Cell Biol (1992) 3.37
Synthesis of hepatitis B surface antigen in mammalian cells: expression of the entire gene and the coding region. J Virol (1983) 3.24
p53 in growth control and neoplasia. Biochim Biophys Acta (1996) 3.19
The WW domain: a signalling site in dystrophin? Trends Biochem Sci (1994) 3.18
Human p53 cellular tumor antigen: cDNA sequence and expression in COS cells. EMBO J (1985) 3.18
p53 cellular tumor antigen: analysis of mRNA levels in normal adult tissues, embryos, and tumors. Mol Cell Biol (1985) 3.13
Structure of the WW domain of a kinase-associated protein complexed with a proline-rich peptide. Nature (1996) 3.11
Base pairing of RNA I with its complementary sequence in the primer precursor inhibits ColE1 replication. Nature (1981) 3.11
Solving the structure of human H ferritin by genetically engineering intermolecular crystal contacts. Nature (1991) 3.10
WW domains and retrovirus budding. Nature (1996) 3.10
Wild type p53 can mediate sequence-specific transactivation of an internal promoter within the mdm2 gene. Oncogene (1993) 3.08
Binding specificity and in vivo targets of the EH domain, a novel protein-protein interaction module. Genes Dev (1997) 3.01
A single gene and a pseudogene for the cellular tumour antigen p53. Nature (1984) 2.98
Specific interaction between the p53 cellular tumour antigen and major heat shock proteins. Nature (1986) 2.94
Analysis of the gene coding for the murine cellular tumour antigen p53. EMBO J (1984) 2.94
Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum (2009) 2.92
p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. J Exp Med (1998) 2.91
Promoter of a eukaryotic tRNAPro gene is composed of three noncontiguous regions. Proc Natl Acad Sci U S A (1982) 2.91
Regulation of mdm2 expression by p53: alternative promoters produce transcripts with nonidentical translation potential. Genes Dev (1994) 2.88
Rapid ATM-dependent phosphorylation of MDM2 precedes p53 accumulation in response to DNA damage. Proc Natl Acad Sci U S A (1999) 2.87
p53-independent upregulation of miR-34a during oncogene-induced senescence represses MYC. Cell Death Differ (2009) 2.80
Association of the polyomavirus middle-T antigen with c-yes protein. Nature (1987) 2.78
Differential affinities of simian virus 40 large tumor antigen for DNA. Proc Natl Acad Sci U S A (1980) 2.75
Overproduction of p53 antigen makes established cells highly tumorigenic. Nature (1985) 2.72
Meth A fibrosarcoma cells express two transforming mutant p53 species. Oncogene (1988) 2.71
Non-visualization of the cavum septi pellucidi is not synonymous with agenesis of the corpus callosum. Ultrasound Obstet Gynecol (2012) 2.65
Critical role for Ser20 of human p53 in the negative regulation of p53 by Mdm2. EMBO J (1999) 2.64
Transcription by RNA polymerase III. Curr Top Dev Biol (1983) 2.63
Control of ColE1 DNA replication: the rop gene product negatively affects transcription from the replication primer promoter. Proc Natl Acad Sci U S A (1982) 2.56
Localization of gene for human p53 tumour antigen to band 17p13. Nature (1986) 2.56
The most abundant small cytoplasmic RNA of Saccharomyces cerevisiae has an important function required for normal cell growth. Mol Cell Biol (1989) 2.55
Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. Oncogene (1999) 2.43
Differences in abuse reported by female and male Canadian medical students. CMAJ (1994) 2.41
Cloning of several cDNA segments coding for human liver proteins. EMBO J (1983) 2.32
Partial purification and properties of two forms of deoxyribonucleic acid polymerase from calf thymus. J Biol Chem (1973) 2.31
Opposing effects of Ras on p53: transcriptional activation of mdm2 and induction of p19ARF. Cell (2000) 2.30
p53-mediated cell death: relationship to cell cycle control. Mol Cell Biol (1993) 2.27
TAp73/Delta Np73 influences apoptotic response, chemosensitivity and prognosis in hepatocellular carcinoma. Cell Death Differ (2005) 2.25
A functional p53-responsive intronic promoter is contained within the human mdm2 gene. Nucleic Acids Res (1995) 2.23
Different tumor-derived p53 mutants exhibit distinct biological activities. Science (1990) 2.20
Hepatitis B virus DNA contains a glucocorticoid-responsive element. Proc Natl Acad Sci U S A (1986) 2.18
Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13). Nat Biotechnol (2000) 2.18
The 5' region of the p53 gene: evolutionary conservation and evidence for a negative regulatory element. EMBO J (1985) 2.17
Intersectin, a novel adaptor protein with two Eps15 homology and five Src homology 3 domains. J Biol Chem (1998) 2.13
Specific loss of apoptotic but not cell-cycle arrest function in a human tumor derived p53 mutant. EMBO J (1996) 2.12
Yes-associated protein 65 localizes p62(c-Yes) to the apical compartment of airway epithelia by association with EBP50. J Cell Biol (1999) 2.11
Regulation of p53 stability and p53-dependent apoptosis by NADH quinone oxidoreductase 1. Proc Natl Acad Sci U S A (2001) 2.10
Characterization of the WW domain of human yes-associated protein and its polyproline-containing ligands. J Biol Chem (1997) 2.08
A novel leader peptide which allows efficient secretion of a fragment of human interleukin 1 beta in Saccharomyces cerevisiae. EMBO J (1987) 2.05
Properties of permissive monkey cells transformed by UV-irradiated simian virus 40. J Virol (1977) 2.03
Mutant p53 gain of function: reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression. Oncogene (2006) 2.01
Health risks posed by use of Di-2-ethylhexyl phthalate (DEHP) in PVC medical devices: a critical review. Am J Ind Med (2001) 2.00
MDM2 suppresses p73 function without promoting p73 degradation. Mol Cell Biol (1999) 2.00
A mutant p53 that discriminates between p53-responsive genes cannot induce apoptosis. Mol Cell Biol (1996) 1.98
Cooperation of the tumour suppressors IRF-1 and p53 in response to DNA damage. Nature (1996) 1.98
Oligomerization of oncoprotein p53. J Virol (1988) 1.98
The WW domain of neural protein FE65 interacts with proline-rich motifs in Mena, the mammalian homolog of Drosophila enabled. J Biol Chem (1997) 1.92
Selection of antibody ligands from a large library of oligopeptides expressed on a multivalent exposition vector. J Mol Biol (1991) 1.90
Structure of a WW domain containing fragment of dystrophin in complex with beta-dystroglycan. Nat Struct Biol (2000) 1.89
Liver-specific expression of hepatitis B virus is determined by the combined action of the core gene promoter and the enhancer. J Virol (1989) 1.88
SV40 large tumor antigen can regulate some cellular transcripts in a positive fashion. Cell (1982) 1.85
Age-related loss of axospinous synapses formed by two afferent systems in the rat dentate gyrus as revealed by the unbiased stereological dissector technique. Hippocampus (1992) 1.85
Heterogeneity of "virus-like" genes encoding retrovirus-associated 30S RNA and their organization within the mouse genome. Cell (1980) 1.85
IgA antibodies to tissue transglutaminase: An effective diagnostic test for celiac disease. J Pediatr (1999) 1.82
Cell type-specific inhibition of p53-mediated apoptosis by mdm2. EMBO J (1996) 1.82
Regulation of the cellular p53 tumor antigen in teratocarcinoma cells and their differentiated progeny. Mol Cell Biol (1982) 1.82
Cellular factors that interact with the hepatitis B virus enhancer. Mol Cell Biol (1989) 1.78
Identification of the ferroxidase centre in ferritin. FEBS Lett (1989) 1.78
One-year follow-up after laparoscopic Heller-Dor operation for esophageal achalasia. Surg Endosc (1997) 1.78